Neogenomics Inc (NASDAQ: NEO) is -38.77% lower on its value in year-to-date trading and has touched a low of $8.05 and a high of $19.11 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NEO stock was last observed hovering at around $9.91 in the last trading session, with the day’s gains setting it 0.18%.
Currently trading at $10.09, the stock is 7.98% and -0.55% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.04 million and changing 1.82% at the moment leaves the stock -28.80% off its SMA200. NEO registered -24.81% loss for a year compared to 6-month loss of -23.15%. The firm has a 50-day simple moving average (SMA 50) of $10.1464 and a 200-day simple moving average (SMA200) of $14.17065.
The stock witnessed a 1.31% gain in the last 1 month and extending the period to 3 months gives it a -31.17%, and is 5.54% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.49% over the week and 7.29% over the month.
Neogenomics Inc (NEO) has around 2200 employees, a market worth around $1.30B and $660.57M in sales. Fwd P/E is 28.64. Profit margin for the company is -11.92%. Distance from 52-week low is 25.34% and -47.21% from its 52-week high. The company has generated returns on investments over the last 12 months (-6.04%).
with sales reaching $170.9M over the same period.The EPS is expected to grow by 63.59% this year, but quarterly earnings will post 11.76% year-over-year. Quarterly sales are estimated to grow 9.38% in year-over-year returns.
350.0 institutions hold shares in Neogenomics Inc (NEO), with institutional investors hold 103.29% of the company’s shares. The shares outstanding are 128.15M, and float is at 127.12M with Short Float at 3.81%. Institutions hold 102.19% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 19.67 million shares valued at $272.82 million. The investor’s holdings represent 15.5612 of the NEO Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 14.12 million shares valued at $195.87 million to account for 11.1716 of the shares outstanding. The other top investors are BROWN ADVISORY INC which holds 8.77 million shares representing 6.9391 and valued at over $121.66 million, while T. ROWE PRICE INVESTMENT MANAGEMENT, INC. holds 5.3244 of the shares totaling 6.73 million with a market value of $93.35 million.
Neogenomics Inc (NEO) Insider Activity
The most recent transaction is an insider sale by Olivo Alicia C, the company’s General Counsel. SEC filings show that Olivo Alicia C sold 5,175 shares of the company’s common stock on Nov 15 ’24 at a price of $15.36 per share for a total of $79475.0. Following the sale, the insider now owns 37129.0 shares.
Still, SEC filings show that on Aug 15 ’24, Olivo Alicia C (General Counsel) disposed off 1,040 shares at an average price of $16.05 for $16695.0. The insider now directly holds 43,813 shares of Neogenomics Inc (NEO).
